John Mascarenhas/primeinc.org
Mar 27, 2025, 07:24
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis – Mount Sinai Department of Medicine
Mount Sinai Department of Medicine shared a post on LinkedIn:
“John Mascarenhas, MD, discusses his research on myelofibrosis – the first study to evaluate a combination therapy approach instead of a single treatment.
“We are hopeful this study will mark the beginning of a new era in myelofibrosis treatment,” said Dr. Mascarenhas. “Our findings highlight the potential of combination therapies to achieve deeper and more durable responses.”
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Authors: Raajit K. Rampal, John Mascarenhas et al.
Aaron T. Gerds
Alberto Álvarez-Larrán
Alessandro Lucchesi
Alessandro M. Vannucchi
Andrea Patriarca
Andrew T. Kuykendall
Anna-Maria Jegg
Barbara Brown
cancer
Claire N. Harrison
David Lavie
Dominik Chraniuk
Elisabetta Abruzzese
Francesca Palandri
Jean-Jacques Kiladjian
John Mascarenhas
Joseph M. Scandura
Morgan Harris
Moshe Talpaz
OncoDaily
Oncology
Prithviraj Bose
Qing Li
Raajit K. Rampal
Rainer Boxhammer
Ruben Mesa
Sarah-Katharina Kays
Sebastian Grosicki
Stephen T. Oh
Sung-Eun Lee
Vikas Gupta
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 29, 2025, 20:53